when a drug company starts research on a particular drug for lets say cancer and this drug shows promising results in the lab how long would it normally take to get it patened and FDA approved assuming of course the setbacks were minimul
U could very well be right. My opinion based on long term success of this company, their pipeline, and divident. If it drops as ur TA says, opportunity to accumulate.
Agree is a great entry point to buy a few shares as possible lower downside based on TA. Reason down has to be about the contact pricing that just took place in court.. Do we know what this product contributes to their sales? We are just at support and hope we can hold it. IMO Think 100 doable and 105 could be seen in mid fall providing they hit ER estimates.
My partner bought some for me back in 1994 or 1995. I forget.. but I am thinking of cashing in soon.
These bills seems to be piling up.
You do, of course, realize that there's more than one Kenny on the face of this Earth, right? Your Mama didn't patent your name.
In ignoring me, you've wounded me deeply. I'll lose sleep, think about it endlessly.
I looked at your past posts and you have offered nothing but insults to someone named Kenny. You have no knowledge of anything about investing and are just a plain little simpleton. And now you're blocked form my posts. And today was the first time i ever posted on this site. Now go play with yourself. It's obvious you do that a LOT.
If you're talking to me I am not impotent, been married for 34 years, have 5 children, live in Florida since 1977 and been retired since my 50's. Now who's the dum-dum axxhole. You have a terrible attitude. probably comes from being a lousy investor.
98 to 101 check the charts, 2 to 3 point swings over the past 8 months.
Buy it here and it'll soon be 101,,
Yes, Afrezza is the very best (by a long shot) short acting, monomeric insulin with almost zero side effects and the best safety profile. Get in before the DTC begins in a few weeks: MNKD
It WAS over $109.00 at one point. It has been on a long slide down for a while now.
Genmab held a presentation at Goldman Sachs 9th june 2015 following ASCO and recent BLA filing for Daratumumab.
It was a 34 minute long Q&A session where we got some more insights in details in manufacturing and how Genmab sees the future of Daratumumab.
The US plays a big role in any biotech and pharma company by the sheer size of their global share of the market. As a rule of thumb, 50% of all revenues historically comes from the US.
Genmab is getting more US shareholders and is starting to focus more on roadshows in the US. They already have an ADR which makes it easier for American retail investors to buy. In time they will probably also have a seperate listing in the US, but for now they will keep it in Europe according to Jan Van de Winkel.
Genmab has delivered to their stakeholders during the last 4 years. This perpetual delivery drives the valuation of the company higher, and at this point Genmab is valued at 5,5 billion dollars.
That translates into a 2000% (thousands!) increase in value over 3 years. The questions for new and existing shareholders is whether there is more to come.
The answer will in part come from the approval and market penetration of Daratumab in 2016.
But the underlying reason for the retained value for the investors has to do with -the now not so new – management team, David Eatwell and Jan Van de Winkel, have succeeded with 3 important goals.
Read more here : http://inrater.com/genmab-unfolding-daratumumab/
Forget the others; these guys are the real deal. I am up 600% thanks to Ultimate Stock Alerts (look them up in Google)